|
| 37067911 | Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program. | Cancer Discov | 2023 |
| 37579145 | Triple-negative breast tumors are dependent on mutant p53 for growth and survival. | Proc Natl Acad Sci U S A | 2023 |
| 37633949 | The histone chaperone function of Daxx is dispensable for embryonic development. | Cell Death Dis | 2023 |
| 34601571 | Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. | Blood | 2022 |
| 35320355 | Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo. | Cancer Res | 2022 |
| 35017466 | Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). | Blood Cancer J | 2022 |
| 33881933 | Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. | J Urol | 2021 |
| 32900967 | p53 drives a transcriptional program that elicits a non-cell-autonomous response and alters cell state in vivo. | Proc Natl Acad Sci U S A | 2020 |
| 32156729 | Men1 maintains exocrine pancreas homeostasis in response to inflammation and oncogenic stress. | Proc Natl Acad Sci U S A | 2020 |
| 32821827 | Daxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo. | Sci Adv | 2020 |
| 32745468 | Intestinal Epithelial TBK1 Prevents Differentiation of T-helper 17 Cells and Tumorigenesis in Mice. | Gastroenterology | 2020 |
| 31517177 | Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. | JCO Precis Oncol | 2019 |
| 30459358 | Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux. | Oncogene | 2019 |
| 31231128 | Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. | Mod Pathol | 2019 |
| 27941886 | c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun. | Oncogene | 2017 |
| 28601352 | Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. | Eur Urol | 2017 |
| 28529618 | Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. | J Cancer | 2017 |
| 29050296 | Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. | Oncotarget | 2017 |
| 29156801 | Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. | Oncotarget | 2017 |
| 27806325 | Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. | Oncotarget | 2016 |
| 26787237 | Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. | Ann Oncol | 2016 |
| 26420498 | Characterization of DNA variants in the human kinome in breast cancer. | Sci Rep | 2015 |
| 25626406 | Clinical actionability enhanced through deep targeted sequencing of solid tumors. | Clin Chem | 2015 |
| 25429071 | Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. | Journal of Immunology | 2015 |
| 26136146 | Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments. | PLoS One | 2015 |
| 24957076 | Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. | J Natl Cancer Inst | 2014 |
| 25172932 | Gene signature-guided dasatinib therapy in metastatic breast cancer. | Clin Cancer Res | 2014 |
| 25003837 | Blocking the formation of radiation-induced breast cancer stem cells. | Oncotarget | 2014 |
| 25239934 | Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC. | Molecular Cancer Therapeutics | 2014 |
| 23504136 | A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories. | Breast Cancer Res Treat | 2013 |
| 26484051 | Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients. | Genom Data | 2013 |
| 24060333 | Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. | Breast Cancer Res | 2013 |
| 23874497 | Bayesian mixture models for assessment of gene differential behaviour and prediction of pCR through the integration of copy number and gene expression data. | PLoS ONE | 2013 |
| 23158478 | Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial. | BMC Medical Genomics | 2012 |
| 22343619 | A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. | Br J Cancer | 2012 |
| 22291085 | Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. | J Clin Oncol | 2012 |
| 22538770 | Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. | Breast Cancer Res Treat | 2012 |
| 22559056 | Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. | Breast Cancer Research | 2012 |
| 22132775 | Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems. | BMC Bioinformatics | 2011 |
| 21248301 | Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. | Clin Cancer Res | 2011 |
| 21153052 | Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. | Breast Cancer Res Treat | 2011 |
| 21422418 | Multifactorial approach to predicting resistance to anthracyclines. | J Clin Oncol | 2011 |
| 21191116 | Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. | J Natl Cancer Inst | 2011 |
| 20360852 | SWISS MADE: Standardized WithIn Class Sum of Squares to evaluate methodologies and dataset elements. | PLoS One | 2010 |
| 20024612 | Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. | Breast Cancer Res Treat | 2010 |
| 20068086 | Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. | Clin Cancer Res | 2010 |
| 20129251 | Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. | Cancer Cell | 2010 |
| 20959472 | Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. | Cancer Res | 2010 |
| 20829329 | Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. | Clin Cancer Res | 2010 |
| 20805453 | Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. | J Clin Oncol | 2010 |